Gulay Bulut1, Zehra Kurdoglu2, Yeliz Bozdemir Dönmez3, Mertihan Kurdoglu4, Remzi Erten1. 1. Department of Pathology, Yuzuncu Yil University Faculty of Medicine Van, Turkey. 2. Department of Obstetrics and Gynecology, Ankara Education and Research Hospital Ankara, Turkey. 3. Department of Histology and Embryology, Faculty of Medicine, Namık Kemal University Tekirdag-Turkey. 4. Department of Obstetrics and Gynecology, Faculty of Medicine, Gazi University Ankara, Turkey.
Abstract
OBJECTIVE: In our study, we aimed to investigate the effects of Jun N-terminal kinase inhibitor (SP600125) on fibrosis and inflammation in rats with polycystic ovary syndrome (PCOS). METHOD: 50 Wistar-albino rats were divided into five groups (n=10 each): control group, sham group, PCOS group, SP600125+ PCOS group and SP600125 group. In the estradiol valerate (EV)-treated group in which PCOS was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil and the rats were sacrificed on day 60. The estradiol valerate (EV)-treated + SP600125-treated group was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil. As of day 60, the treatment group was additionally given 15 mg/kg i.p. of SP600125 once daily for 4 consecutive days and the rats were sacrificed on day 65. Histopathological findings (ovarian morphology, edema, inflammatory cell infiltration, vascular congestion and hyperemia) and collagen type IV immunoexpression were assessed. RESULTS: The SP600125+ PCOS group showed a significant level of improvement in ovarian follicle morphology, edema, inflammatory infiltrate, vascular congestion and hyperemia as compared with the PCOS group. Furthermore, collagen type IV immunoexpression showed a significant reduction in staining intensity on the theca cell layer and ovary stroma as compared to the PCOS group. CONCLUSION: This study demonstrates the therapeutic effect of SP600125 in the prevention of PCOS in an experimental model.
OBJECTIVE: In our study, we aimed to investigate the effects of Jun N-terminal kinase inhibitor (SP600125) on fibrosis and inflammation in rats with polycystic ovary syndrome (PCOS). METHOD: 50 Wistar-albino rats were divided into five groups (n=10 each): control group, sham group, PCOS group, SP600125+ PCOS group and SP600125 group. In the estradiol valerate (EV)-treated group in which PCOS was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil and the rats were sacrificed on day 60. The estradiol valerate (EV)-treated + SP600125-treated group was injected with a single 4 mg/kg i.p. of EV in 0.2 ml sesame oil. As of day 60, the treatment group was additionally given 15 mg/kg i.p. of SP600125 once daily for 4 consecutive days and the rats were sacrificed on day 65. Histopathological findings (ovarian morphology, edema, inflammatory cell infiltration, vascular congestion and hyperemia) and collagen type IV immunoexpression were assessed. RESULTS: The SP600125+ PCOS group showed a significant level of improvement in ovarian follicle morphology, edema, inflammatory infiltrate, vascular congestion and hyperemia as compared with the PCOS group. Furthermore, collagen type IV immunoexpression showed a significant reduction in staining intensity on the theca cell layer and ovary stroma as compared to the PCOS group. CONCLUSION: This study demonstrates the therapeutic effect of SP600125 in the prevention of PCOS in an experimental model.
Entities:
Keywords:
Fibrosis; Jun N-terminal kinase inhibitor; inflammation; polycystic ovary syndrome
Authors: Véronique Plantevin Krenitsky; Lisa Nadolny; Mercedes Delgado; Leticia Ayala; Steven S Clareen; Robert Hilgraf; Ronald Albers; Sayee Hegde; Neil D'Sidocky; John Sapienza; Jonathan Wright; Meg McCarrick; Sogole Bahmanyar; Philip Chamberlain; Silvia L Delker; Jeff Muir; David Giegel; Li Xu; Maria Celeridad; Jeff Lachowitzer; Brydon Bennett; Mehran Moghaddam; Oleg Khatsenko; Jason Katz; Rachel Fan; April Bai; Yang Tang; Michael A Shirley; Brent Benish; Tracey Bodine; Kate Blease; Heather Raymon; Brian E Cathers; Yoshitaka Satoh Journal: Bioorg Med Chem Lett Date: 2011-12-10 Impact factor: 2.823
Authors: E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: Shawn M Briley; Susmita Jasti; Jennifer M McCracken; Jessica E Hornick; Barbara Fegley; Michele T Pritchard; Francesca E Duncan Journal: Reproduction Date: 2016-09 Impact factor: 3.906